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1. Introduction 
Overview of diverse functional aspects  
Human platelets (PLTs) are anucleate, discoid small cells (2 - 4 µm by 0.5 µm) that 
normally circulate at concentrations of 150 - 400 x 109/L for a maximum of 10 days. They 
are primed to undergo explosive activation following damage from the vessel wall and 
play a central role in both primary hemostasis and arterial thrombosis, including 
adhesion, aggregation, and coagulation but also chemotaxis, inflammation, and 
proliferation.  
The normal vascular endothelium produces potent PLT inhibitors such as nitric oxide, 
prostacyclin and natural ADPase (CD39). However, once sub-endothelial components like 
collagen, fibronectin, laminin, or von Willebrand factor (vWF) become exposed, PLTs 
undergo a highly regulated set of functional responses including adhesion, followed by 
spreading, release reactions (degranulation), induction of pro-coagulant activity, 
microparticle formation, and clot retraction. These activities result in rapid formation of a 
vascular (white) plug, which then is stabilized by the activation of soluble plasma 
components resulting in the formation of fibrin and the inclusion of erythrocytes and 
leukocytes. This red plug initiates the healing process during which a part of fibrin is 
degraded again by fibrinolysis. Under physiological conditions thrombus formation is 
strongly limited to the region of the damaged vessel wall by inhibitory mechanisms of intact 
endothelial cells and the coagulation cascade. 
PLTs are enriched in surface glycoprotein (GP) receptors that mediate interactions among 
PLTs themselves, with the sub-endothelium and with white blood cells. PLTs also contain 
specific granules for the storage of calcium (Ca++), adenine/guanine nucleotides, and 
serotonin (dense bodies) and the storage of coagulation factors (e.g. vWF, FV), multimerin, 
thrombospondin-1, fibrinogen, IgE, growth factors (e.g. PDGF, TGF-ǃ, ECGF, EGF, VEGF, 
bFGF, IGF-I), and cytokines (e.g. PF4, RANTES) (ǂ granules). Serotonin (5-
hydroxytryptamine) acts predominantly as a local vasoconstrictor but has also pro-
inflammatory properties by stimulation of monocytes and attraction of T lymphocytes (IL-
16). Contents of ǂ granules mediate e.g. host defense, recruitment and activation of 
leukocytes as well as regulation of tissue repair by mitogenic effects on smooth muscle cells, 
macrophages, monocytes, and fibroblasts. Other important pro-inflammatory mediators are 
present in the cytosol (IL-1ǃ, CD40L) and are generated from mRNA (relict from 
megacaryocytes) and are released upon PLT activation. CD40L stabilizes aggregation by 
interference with GP IIb-IIIa and stimulates endothelial cells to express ICAM-1, VCAM-1, 
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E-selectin, and the vitronectin receptor, thus modulates leukocyte-endothelium and PLT-
endothelium interactions.  
Due to specific binding between sub-endothelial agents and specific GP receptors, PLTs 
begin to slow down and transiently adhere or roll along the damaged area of the vessel wall. 
Under conditions of high shear, as found in the arterial circulation, the initial PLT-sub-
endothelium interactions are exclusively mediated by vWF present in bridges between sub-
endothelial collagen and GP Ib (V-IX) of the adhering PLTs. The following steps of 
activation via various signal transduction pathways (outside-in signaling) and the elevation 
of cytoplasmatic Ca++ levels are then mediated by other receptor-ligand interactions. When 
the cytoplasmatic Ca++ concentration exceeds a certain threshold, cytoskeletal changes 
occur, which mediate shape change from discoid to sphere, pseudopod formation, and 
conformational change of the fibrinogen receptor GP IIb-IIIa (receptor activation). Only the 
activated GP IIb-IIIa complex is able to bind soluble plasma fibrinogen (and vWF under 
high shear conditions) leading to further spreading of the stimulated PLTs along the site of 
injury and ultimate aggregation characterized by fibrinogen bridges between the activated 
GP IIb-IIIa complexes on adjacent PLTs. Simultaneous release and surface exposure of 
granule components (e.g. ADP and serotonin from dense bodies, vWF and p selectin from ǂ-
granules) and cyclooxygenase (COX)-related thromboxane A2 (TxA2) formation/expression 
result in further recruitment, activation and aggregation of other PLTs near to the growing 
plug. At least, internal, anionic, negatively charged phospholipids are exposed by 
transbilayer flip flop of the inner membrane leaflet and pro-coagulant microvesicles are 
generated. The exposure of anionic phospholipids, mainly phosphatidylserine, provides a 
surface upon which PLTs can support thrombin generation by accelerating the tenase and 
prothrombinase reactions of the plasmatic coagulation pathway. Thrombin, the key enzyme 
of the coagulation cascade and the most potent PLT agonist, interacts with two binding sites 
on PLTs, a) the region of GP Ib (high affinity) and b) a specific epitope of the thrombin 
receptor (moderate affinity). Binding of thrombin leads to cleavage of the extracellular 
domain (protease-activated receptor PAR), whereby the generated free polypeptide 
(SFLLRN-x) can directly activate further thrombin receptors (thrombin-receptor activating 
peptide TRAP). Human PLTs express two kinds of PARs activated either by lower (PAR-1) 
or higher concentrations of thrombin (PAR-4). Receptor activation by thrombin results in 
further activation of GP IIb-IIIa, TxA2 formation, and secretion of granular components such 
as ADP that promotes recruitment and activation of adjacent PLTs into the vicinity of the 
growing plug and the inclusion of leukocytes. Thrombin also converts soluble fibrinogen 
into insoluble fibrin, which is cross-linked by the thrombin-activated FXIII to confer stability 
of the otherwise fragile plug/thrombus. At last, the activated PLTs rearrange their 
intracellular actin/myosin cytoskeleton, which leads to clot retraction. The latter is inhibited 
by blockade of GP IIb-IIIa receptors representing central links between the contractile 
elements.  
Adhesion 
As described, adhesion is mediated by GPs of the PLT surface that recognize specific 
structural components of the extracellular matrix such as collagen and elastic fibrils 
embedded in a gel of proteoglycans and water. This first contact (contact phase) between 
PLTs and the sub-endothelium is mediated by interaction between GP Ib-V-IX (vWF 
receptor belonging to the leucine-rich GPs) with collagen-bound vWF. Thus, the main task 
of GP Ib-V-IX is the adhesion of circulating PLTs to immobilized vWF despite high shear 
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forces. GP Ib-V-IX consists of four subunits: the central part is GP V surrounded by GP Ibǂ 
and GP Ibǃ, which are covalently linked to each other by disulfide bridges and non-
covalently bound to GP IX. GP Ibǂ possesses binding sites for vWF and thrombin. In 
contrast to GP IIb-IIIa, whose surface expression increases after thrombin activation, the 
surface density of GP Ib-V-IX is reduced by receptor internalization after PLT activation. 
Recent evidence suggests that, apart from GP Ib-V-IX, another PLT membrane receptor for 
collagen, GP VI, is strictly required for the initial PLT tethering following vascular injury. 
Both receptors appear to act in concert to recruit PLTs to the sub-endothelium in-vivo. GP 
VI mediates the activation (opening) of other adhesive receptors (GP IIb-IIIa, GP Ia-IIa) by 
shifting them from a low to a high affinity binding state required for stable PLT arrest. GP 
VI belongs to the immunoglobulin superfamily and forms complexes with the FcR ʏ-chain at 
the cell surface. In the absence of GP VI, PLTs completely failed to adhere and aggregate on 
the damaged vessel wall. Further immunoglobulin adhesion receptors, PECAM (PLT-
endothelial cell adhesion molecule)-1 and ICAM (intracellular adhesion molecule)-2 
probably mediate adhesion to leukocytes and PLT related inflammation, but their global 
role for PLT function is mostly unknown. 
The contact phase is stabilized via further adhesion to collagen, fibronectin, laminin, and 
thrombospondin (stabilization phase). Binding of collagen leads to the formation of 
pseudopods (shape change) and peptide as well as GP IIb-IIIa activation via tyrosine 
phosphorylation (activation phase). Starting from released arachidonic acid (AA) the 
adhering PLTs form TxA2, which slows down the blood flow due to its vasoconstricting 
activity. Additionally TxA2 induces the release of soluble granule components like ADP 
(secretion phase) leading to the recruitment of still resting PLTs that then become activated 
and aggregate with already adhering PLTs through activated GP IIb-IIIa. By spreading of 
the PLT aggregate over the complete sub-endothelium, the vessel wall lesion is separated 
from blood flow, and blood loss is kept as low as possible. 
Aggregation 
Aggregation depends on three conditions: shear force, Ca++, and fibrinogen. The latter are 
stored in PLT granules and are released in high concentrations during PLT activation. While 
the primary aggregation phase is reversible and characterized by “loose links” via fibrinogen 
bridges, the secondary aggregation phase is irreversible and induced by the degranulation 
process. GP IIb-IIIa, a ǃ3 integrin, plays a central role in aggregation. 60,000 to 100,000 GP 
IIb-IIIa receptors can be detected per PLT. 70% are bound to the surface, and 30% are only 
released from intracellular stores (open canalicular system, ǂ-granules) upon PLT activation. 
Circulating PLTs carry resting, not activated GP IIb-IIIa complexes (low affinity functional 
state) that only can bind immobilized fibrinogen. The binding sites for soluble fibrinogen 
become accessible after conformational change during activation, which strongly depends 
on Ca++ (high affinity functional state). The binding of fibrinogen to the activated receptor 
induces a further conformational change (ligand-occupied functional state) with exposure of 
cryptic epitopes (LIBS = ligand-induced binding site) and transmembrane signal 
transduction (post-occupancy) events.  
Activation 
Upon changes in biochemical pathways several soluble PLT agonists (e.g. ADP, thrombin, 
TxA2) are formed, which bind to specific G protein-linked receptors. Via signal transduction 
pathways, each agonist amplifies the activation step through the formation of second 
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messengers. One of these messengers, phospholipase C, forms inositol 1,4,5 triphosphate (IP3) 
and diacylglycerol (DAG), whereby IP3 enhances the intracellular Ca++ concentration and 
DAG activates proteinkinase C, which in turn phosphorylates a series of further signal 
proteins that control the degranulation process and the activation of GP IIb-IIIa. 
Cytoplasmatic Ca++ activates phospholipase A2, which leads to the liberation of AA from 
phospholipids of the cell membrane. Aspirin-sensitive COX-1 and thromboxane synthetase 
then form TxA2, which has vasoconstricting activity and stimulates the secretion of granule 
components after interaction with specific TxA2 receptors. Two TxA2 receptors can be 
distinguished on the PLTs surface (TPǂ and TPǃ), of which TPǂ is most important. COX-1-
inhibition results in reduced secretion and inhibition of secondary aggregation. Receptors 
that directly inhibit PLTs stimulate adenylate cyclase (increased formation of cAMT) via GS 
proteins and are activated by PLT antagonists like adenosine, ǃ-adrenergic substances, 
prostacyclin, prostaglandin E1, and theophylline. 
PLTs are presently the only cells that express ADP specific receptors (P2Y1, P2Y12, P2X1). Like 
other activation receptors, ADP receptors are linked to G-proteins. Due to their key role in 
the pathogenesis of arterial thrombosis, they are of particular pharmacological interest. The 
P2Y1 receptor is linked to the initiation of shape change, mediation of Ca++ mobilization and 
activation of phospholipase C. Activation of P2Y12 inhibits cAMP formation via inhibitory G-
proteins and is predominantly responsible for TxA2 formation, p selectin surface expression 
and conformational changes of GP IIb-IIIa (receptor activation), thus sustained PLT 
aggregation. All of these mechanisms are affected by thienopyridines. Like P2Y1, P2X1 
mediates Ca++ influx and shape change but seems not to be influenced by thienopyridines. 
Secretion 
During adhesion, PLTs begin to release stored components from the granules in the order 
dense bodies, ǂ-granules, and lysosomes. Dependent on ATP and Ca++ the degranulation 
process initiates the secondary, irreversible phase of aggregation and reinforces the 
activation/recruitment of further circulating PLTs as well as fibrin formation resulting in 
thrombus consolidation. As described above, the interaction of released ADP (from PLTs, 
damaged vessel wall cells, endothelial cells, red blood cells) with its specific purinergic 
receptors plays a central role in this process. Released serotonin reinforces vasoconstriction 
and thus slows down the blood flow. Released ǂ-granule contents attract leukocytes and 
fibroblasts (ǃ-TG, PF4), promote mitogenic and proliferative effects in fibroblasts and 
smooth muscle cells (growth factors like PDGF), or exhibit pro-inflammatory activity (IL-1). 
P selectin is found in both PLTs (ǂ-granules) and endothelial cells (Weibel-Palade bodies) 
and is expressed on cell surface only after cellular activation. P selectin is the decisive 
receptor for PLT adhesion to leukocytes and triggers inflammatory reactions but also plays a 
central part in vascular repair processes. Interestingly, p selectin is significantly increased in 
all states of coronary artery disease: stable angina (showing also increased TxA2 formation 
and fibrinogen binding due to increased GP Ib and GP IIb-IIIa expression [1-3]), unstable 
angina (showing also increased LIBS expression [4]), and acute myocardial infarction (AMI). 
Here, increased p selectin levels are indicative for an increased thrombotic re-occlusion risk 
[5]. When coronary stenting is combined with dual antiplatelet therapy, p selectin 
expression and GP IIb-IIIa activation are as low as after conventional coronary angioplasty 
[6-8]. Besides p selectin, thrombin promotes chemotaxis of monocytes and mitogenesis in 
lymphocytes and mesenchymal cells (smooth muscle cells, fibroblasts). In addition, released 
coagulation factors (vWF, fibrinogen, FV, PAI-1) fulfill pro-coagulant or anti-fibrinolytic 
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tasks. The pro-coagulant activity can be reinforced by microparticle formation, small 
membrane vesicles extruded from activated PLTs that exhibit a high binding affinity for FVa 
and FVIIIa, thus facilitating the formation of the tenase and prothrombinase complexes. 
Lysosomal enzymes like collagenease or elastase degradate surrounding fibrils and induce 
changes in atherosclerotic plaques. 
2. The role of platelets in atherogenesis 
Role of the arterial plaque 
In contrast to stable angina pectoris, which is generally caused by a reduced oxygen supply 
to the myocardium due to coronary vasoconstriction, acute coronary syndromes (ACS) arise 
from an acute plaque rupture within an epicardial coronary artery with subsequent PLT 
aggregation and thrombus formation. Reperfusion strategies aim to dissolve the thrombotic 
plaque either through administration of fibrinolytic agents or direct coronary interventions. 
Paradoxically, despite a sufficiently reestablished blood flow, reperfusion injury occurs and 
myocardial dysfunction can progress. This is mainly triggered by activated PLTs released 
from the plaque area or the circulation itself (cardiovascular risk factors are per se associated 
with an increased basal activity of circulating PLTs [9,10]). Activated PLTs in turn promote 
inflammatory reactions within the ischemic myocardium, thus plug growing. Consequently, 
up to 50% of all patients with successful revascularization and normal epicardial blood flow 
following interventional therapy do not have adequate tissue reperfusion [11,12].  
Following a modern concept of atherogenesis, apart from endothelial dysfunction 
(characterized by decreased vasodilatation upon stimulation with acetylcholine and 
increased pro-coagulant inflammatory activities) lipid deposition on the intima is one of the 
first pathological events in the genesis of an arterial plaque. The lipid-rich nucleus is 
separated from blood flow by a fibrous cap and rich in free cholesterol crystals, cholesteryl 
esters, oxidized LDL and monocytes/macrophages. The latter undergo phagocytosis of fatty 
acids and oxidized LDL and differ to foam cells. Additionally, there are particularly heavy 
PLT deposits and high amounts of tissue factor, which favors thrombin formation. 
Thrombin, in turn, activates additional PLTs and supports their aggregation to already 
adhering PLTs (recruitment), which, in parallel, stimulate the migration of smooth muscle 
cells and fibroblasts by a PDGF-dependent mechanism. After intima proliferation and 
monocyte migration increased shear forces (high blood flow or tension) and the liberation of 
proteolytic enzymes (plasminogen activator, metalloproteinases) can promote plaque 
rupture with all known sequelae. PLTs are not just involved in thrombotic complications by 
formation of vascular occlusions but also trigger plaque progression and promote 
myocardial malperfusion by participation in recurrent vasoconstrictions and local/systemic 
inflammatory reactions.  
PLT-mediated microembolization 
The regeneration of the afflicted myocardial area largely depends on the integrity and 
recovery of the microcirculation distal to the stenosis. Importantly, there is an increased 
embolization of thrombotic material from the arterial plaque lesion during plaque growing 
and particularly in the reperfusion phase after coronary interventions. This may promote 
intermittent coronary vasospasms distal to the stenosis through the release of serotonin and 
TxA2 resulting in inadequate perfusion, myocardial ischemia, tissue damage, unstable 
angina or non-ST-segment elevation myocardial infarction. On the other hand, the contact of 
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intact endothelial cells with activated PLTs has the potential to modify chemotactic, 
proteolytic and adhesive properties inducing increased surface expression of endothelial 
adhesion receptors (VCAM-1, ICAM-1, vitronectin receptor), which participate in the 
recruitment of PLTs to the inflamed endothelium. Additionally, the elevated release of 
endothelial pro-inflammatory substances (MIP-1, IL-6, IL-8) supports chemotaxis, adhesion, 
and transmigration of monocytes. 
PLT-mediated inflammation 
The exposure of sub-endothelial compounds is not required for PLT adhesion in acute 
inflammatory processes such as ischemia/reperfusion. E.g., p selectin expression of 
inflamed endothelial cells has been demonstrated to mediate PLT rolling through GP Ib 
indicating that the vWF receptor mediates both PLT adhesion to the sub-endothelial matrix 
and to “intact” endothelial cells. Additionally, endothelial adhesion receptors that bridge 
PLTs via fibrinogen are up-regulated in response to endothelial inflammation (e.g. by IL-1ǃ 
or CD40L of activated PLTs or thrombin). In this manner, PLTs (if activated or resting) 
adhere to the vessel wall and promote the recruitment of neutrophils and monocytes by the 
release of a variety of pro-inflammatory mediators and growth hormones. Furthermore, 
adhering PLTs can induce up-regulation of NF-κB in endothelial cells leading to further 
inflammatory changes in the vessel wall. High doses of ASA (≥ 900 mg/d) can influence the 
NF-κB activation, thus promote the stillstand of atherosclerotic plaque progression [13]. 
Consequently, cardiac patients with elevated systemic CRP levels benefit especially from 
antiplatelet therapy with ASA [14]. Another strategy to limit reperfusion injury uses 
monoclonal antibodies to adhesion receptors such as p selectin (present on endothelial cells 
and PLTs), CD11/CD18 (present on leukocytes), and the vitronectin receptor (present on 
endothelial cells). Abciximab not only blocks GP IIb-IIIa on PLTs, but also the vitronectin 
receptor on endothelial cells explaining its favorable effect on myocardial perfusion, 
microcirculation, and recovery of left ventricular function [14-17]. 
3. Antiplatelet substances 
Acetylic salicylic acid (ASA) 
Of the five main groups of antiplatelet substances (Tab.1.), ASA is probably the most 
important drug. Its use is considered as the gold standard in primary and secondary 
prophylaxis of coronary syndromes [18]. However, from the results of collagen and AA-
induced aggregation, up to 30% of all patients respond insufficiently to ASA  and may profit 
from a combined (dual) antiplatelet therapy to effectively reduce arterothrombotic events. 
ASA selectively and irreversibly inhibits COX, an ubiquitous enzyme existing in two 
isoforms: COX-1 (forms short living prostaglandins (PgG2, PgH2) from which thromboxane 
synthetase forms TxA2) and COX-2 (forms prostaglandins mainly in leukocytes that are 
involved in inflammatory and pain processes). After oral administration ASA is rapidly (5-
16 min) and completely absorbed. Due to the hepatic first pass effect the bioavailability 
drops to about 50% (Tab.2.). Thereafter, COX-1 of all bypassing PLTs is irreversibly 
acetylated at Ser529. ASA thereby inhibits the production of the potent PLT activator TxA2. 
However, with stronger agonists than TxA2, especially thrombin, PLT aggregation is not 
markedly inhibited by ASA. ASA also inhibits synthesis of prostaglandins in endothelial 
cells (prostacyclin, a potent PLT inhibitor and powerful vasodilatator) and stomach mucosa 
cells (cytoprotective prostaglandins). Of note, in the absence of protein biosynthesis, COX-1  
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Mode of action Substances 
Increase of cyclic nucleotides 
 Activation of adenylat cyclase 
 
 
 Inhibition of phosphodiesterase 
 Activation of guanylyl cyclase 
PGE1 (Alprostadil) 
PGI2 (Epoprostenol) 
prostaglandin (Iloprost) 
theophylline, dipyridamole 
NO, nitrate derivates, molsidomine 
Interaction with arachidonic acid 
metabolism 
 Inhibition of cyclooxygenase 
 
 Inhibition of thromboxyne synthetase 
 Antagonism of TxA2 receptor 
 
acetylsalicylic acid (ASA), sulphinpyrazone, 
indomethazine, ω3-fatty acids 
dazoxibene, ozagrel 
ridogrel, nidrogrel 
Interaction with aggregation receptors 
 Inhibition of ADP receptor 
 Inhibition of thrombin receptor 
 Inhibition of serotonin receptor 
ticlopidine, clopidogrel 
peptide antagonists 
ketanserine 
Inhibition of aggregation 
 Inhibition of fibrinogen receptor (GP 
IIb-IIIa) 
i.v. moAB: abciximab (ReoPro) 
i.v. cyclic peptide: eptifibatide (Integrillin) 
i.v. peptide mimetics: tirofiban, lamifiban 
oral peptide mimetics: xemilofiban, 
orbofibane, gantofibane, roxifiban 
Inhibition of adhesion 
 Inhibition of vWF receptor (GP Ib-V-IX) 
 Inhibition of collagen receptor (GP Ia-IIa)
recombinant vWF fragment 
antibodies, peptides 
 
i.v. intravenous; moAB monoclonal antibody;  
Table 1. Classification of antiplatelet substances [8] 
 
 ASA ticlopidine clopidogrel prasugrel 
Bioavailability (%) 90 80-90 > 50 > 50 
Protein binding (%) 50-80 98 94-98 98 
Half life (h) 0,5 12,6 7-8 > 12 
Metabolism hepatic hepatic hepatic hepatic 
Active metabolites no no yes yes 
Inhibited aggregation (onset) minutes < 4days 2 hours < 30 minutes 
Inhibited aggregation (steady 
state) 
hours 8-11 days 3-7 days 2 days 
Inhibited aggregation (duration) 7 days 5 days 2-3 days 7 days 
Recommended daily dose (mg) 75 - 325 500 (2 x 250) 75 10 
Impairment of hepatic function can diminish the antiplatelet effect. The onset of action of 
thienopyridines can be accelerated by higher initial doses. Compared to clopidogrel, prasugrel 
treatment is associated with more rapid, potent and prolonged PLT inhibition. Preliminary evidence 
suggests a similar safety profile compared to clopidogrel. 
Table 2. Pharmacologic properties of oral antiplatelet drugs [8,23] 
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inhibition in anucleated PLTs persists for a cellular lifetime compared with nucleated 
vascular endothelial and stomach mucosa cells, which recover COX-1 activity shortly after 
exposure to ASA. Daily doses of 30-70 mg ASA are sufficient for complete inhibition of TxA2 
synthesis, whereas increasing doses can promote gastrointestinal side effects. The 
recommended daily dose ranges therefore from 75 to 325 mg. Other side effects include 
intracerebral hemorrhage (≤ 0.5%), hypersensitivity, respiratory alkalosis, and renal and 
liver dysfunction (cave Reye’s syndrome in children characterized by encephalopathy with 
liver damage). Higher doses of ASA inhibit the nuclear factor κB (NF-κB) that regulates 
transcription of many inflammatory cytokines (e.g. MCP-1) and of immunoglobulin 
adhesion receptors (VCAM-1). Additionally, in ACE-inhibitor-treated patients, ASA should 
be replaced with thienopyridines, since much of the hemodynamic benefits of ACE 
inhibitors would be lost by the addition of ASA [19].  
Thienopyridines (TPs) 
TPs including drugs under late state development (cangrelor, elinogrel) inhibit PLT 
adhesion by inhibition of the ADP receptor P2Y12 mediating recruitment and aggregation of 
further PLTs into the vicinity of a growing plug. After oral administration the antiplatelet 
effect is exerted by active metabolites formed by cytochrom (CYP) P450 activity upon 
hepatic metabolism (Tab.2.). Since statins are also metabolized by CPY-P450 (mainly 
CYP3A4), co-administration is associated with decreased antiplatelet efficacy [20]. While 
ticlopidine (oral, approved), clopidogrel (oral, approved) and parasugrel (oral, approved) 
act irreversibly, ticagrelor (oral, approved), cangrelor (intravenous), and elinogrel (oral or 
intravenous) lead to reversible P2Y12 receptor blockade. 
In contrast to ASA, TPs do not influence the COX pathway in endothelial cells (no effect on 
prostacyclin production) but hinder the rapid degradation of extracellular ADP by 
impairment of ectoADPse released from the damaged vessel wall. Considerably more than 
ASA, TPs reduce key factors of arterial thrombosis: shear force-induced PLT activation, 
PLT-leukocyte formation, and inflammation [21]. Consequently, ticlopidine, the first 
developed TP, was found to be superior to ASA in reducing thrombotic risks (mainly 
stroke) during different pathological conditions including percutaneous coronary 
intervention (PCI) [22]. However, due to its unfavorable safety profile (20% diarrhea, 10% 
skin eruptions, 2.5% neutropenia and thrombotic-thrombocytopenic purpura) and its 
delayed onset of action (4-7 days), ticlopidine has been replaced by clopidogrel in routine 
clinical use.  
Clopidogrel, a second generation TP, is equally effective as ticlopidine but has a markedly 
better tolerability profile. Additionally, clopidogrel achieves a significant antiplatelet effect 
even on the first day of treatment. Bleeding problems are as frequent as under ASA [23]. 
Clopidogrel, together with ASA, constitutes the current standard of care for high risk 
patients with cardiovascular diseases and has considerably improved the antithrombotic 
therapy after coronary stenting. Despite this, a considerable number of patients with 
recurrent ischemic cardiovascular events remains, which may only in part be attributed to 
suboptimal PLT inhibition. Less than 60% inhibition of ADP induced PLT aggregation 
following 75 mg/d clopidogrel in healthy volunteers [24] or 300 mg clopidogrel loading in 
PCI patients [25] indicates an incomplete P2Y12 receptor blockade. In addition, inhibited 
ADP induced PLT aggregation < 10% is observed in 10-30% of treated patients [26-31], 
probably due to poor compliance, drug-drug interactions, genetic receptor polymorphisms, 
or variability in CYP P450 activity or intestinal absorption. Poor responsiveness to 
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clopidogrel was shown to be associated with recurrent cardiovascular events including stent 
thrombosis [32] and may be overcome by increased clopidogrel doses. This was 
demonstrated in the CLEAR PLATELETS study, where higher loading doses of clopidogrel 
prior to PCI acted more rapidly and increased the inhibitory effect on PLTs [25]. During 
maintenance, however, there was no significant difference in the composite end point (AMI, 
stroke, vascular death) between the double and the standard dose of clopidogrel [33]. Thus, 
the search for TPs (third generation) with less response variability is an ongoing feature.  
Compared to clopidogrel, cangrelor exhibits more consistent and greater PLT inhibition as 
well as short onset and offset of action. The CHAMPION trials, however, were stopped 
early because of lack of efficiency [34,35]. Cangrelor is still being studied as a bridge for 
clopidogrel prior to surgery [36]. Prasugrel also combines a rapid onset of action (< 30min) 
with less response variability (0.3%) and a prolonged duration of action (> 3 days). While 
ticlopidine and clopidogrel require two CYP P450-dependent steps to form active 
metabolites (mainly CYP 3A4), prasugrel requires only one step (CYP3A4 or CYP2B6). This 
leads to less CYP P450 dependency and higher amounts of active metabolites [37] 
translating into a 10-fold (clopidogrel) to 100-fold (ticlopidine) greater potency [38]. As 
shown in the recent PRINCIPLE-TIMI 44 and TRITON-TIMI 38 studies [39,40], prasugrel 
increased the efficiency of PCI and improved cardiovascular outcomes (by 20%) but was 
associated with a significant increase in major bleedings [41]. This was reinforced by the 
recent CHARISMA trial testing prolonged dual antiplatelet therapy with ASA + prasugrel 
vs. ASA + clopidogrel [42], although the JUMBO-TIMI 26 trial demonstrated a similar 
bleeding risk compared to standard clopidogrel [43]. Prasugrel should not be used in adults 
> 75 years of age or < 60 kg of body weight and in those who have had a recent TIA/stroke 
or an increased bleeding risk. Like prasugrel, ticagrelor acts more potent and rapid but does 
not significantly increase major bleeding events. Drawbacks, however, are increased 
incidences of dyspnea and ventricular pauses [36]. The PLATO study demonstrated 
significantly increased reduction rates of cardiovascular syndromes and mortality vs. 
clopidogrel (- 16%), while bleeding events were as frequent as under prasugrel [44]. In 
addition to cangrelor, prasugrel, and ticagrelor elinogrel rapidly achieves nearly complete 
PLT inhibition even in subjects with low responsiveness to clopidogrel [45]. Patients 
undergoing PCI had greater PLT inhibition under elinogrel (100/150 mg twice daily) than 
under standard clopidogrel without exhibiting more bleeding events [46]. These results gave 
promise for further Phase III trials. 
Fibrinogen receptor antagonists (FRAs) 
FRAs currently prescribed only during PCI reversibly block one of the final steps of PLT 
activation irrespective of the stimulus. This is the binding of fibrinogen to GP IIb-IIIa 
mediating adhesion to the injured vessel wall or interactions with PLTs and other blood 
cells. Blockade of GP IIb-IIIa further leads to an attenuated formation of pro-coagulant 
microparticles and inhibits PLT-dependent formation of thrombin. Thus, in addition to 
inhibition of aggregation, an anticoagulant activity can also be achieved by the 
administration of FRAs. Side effects include hypotension, vertigo, vomiting, headache, and 
thrombocytopenia. Bleeding complications must be considered under ongoing therapy 
(especially in thrombocytopenic, female and elderly patients). 
Chimeric monoclonal antibodies directed against the vicinity of the fibrinogen recognition 
(RGD) region (abciximab) can be distinguished from small low molecular mass antagonists 
(SMAs) including cyclic peptides (eptifibatide) or non-peptide molecules (tirofiban) with a 
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tyrosine like structure (Tab.3). In contrast to SMAs that bind specifically to the RGD region 
(competitive inhibition) abciximab binds to a different site, even when the binding pocket is 
occupied by fibrinogen or vWF (steric inhibirion). 
 
 abciximab eptifibatide tirofiban lamifiban 
Molecular mass (Dalton) 45.000 800 495 468 
Receptor specificity CR no CR no CR no CR 
Onset of action (after i.v. bolus) minutes minutes minutes minutes 
Reversibility slow (> 12 h) rapid (< 6 h) rapid (< 6 h) rapid (< 6 h) 
Half life 
plasma (normally a few hours) 
receptor (normally a few hours) 
short 
long 
DD 
DD 
DD 
DD 
DD 
DD 
Intrinsic activity (LIBS 
expression) 
+ + + + 
Recommended dose 
Initial bolus (µg/kg) prior to PCI 
MD (µg/kg/min) for 12-48 (72) h 
 
250 
0.125 
 
90.0 – 180.0
0.5 – 2.0 
 
0.4 – 10.0 
0.10 – 0.15 
 
- 
0.01 - 0.07 
PCI percutaneous coronary intervention; CR cross reaction with the vitronectin (endothelium cells) and 
the MAC-1 receptor (leukocytes); DD dose dependency; MD maintenance dose 
GP IIb-IIIa blockers administered intravenously (i.v.), have proven efficacious in mitigating arterial 
thrombosis in acute coronary syndromes and coronary interventions such as balloon dilatation and 
stent implantation but are associated with an increased bleeding risk. Currently, i.v. GP IIb-IIIa blockers 
are prescribed in high risk patients with acute coronary syndromes immediately before and after 
coronary intervention (for 24-72 h). Oral GP IIb-IIIa blockers have failed to demonstrate any benefit. 
Table 3. Pharmacologic properties of intravenous (i.v.) GP IIb-IIIa antagonists [8] 
In order to achieve an effective antithrombotic protection, a receptor blockade of at least 
80% should be achieved. A blockade > 90% increases the risk of bleeding. This makes the 
dosing difficult. The latter is controlled by ADP-induced aggregation that should be carried 
out in hirudine- or PPACK-anticoagulated blood due to the Ca++ dependency of receptor 
binding. Unlike abciximab, the function of SMAs depends on the achieved plasma 
concentration. Excretion modalities are linked directly to body weight and are inversely 
correlated with age. Unlike SMAs that rapidly dissociate from the receptor, 70% of all GP 
IIb-IIIa receptors are still inhibited for up to 12 hours after termination of abciximab (PLT 
bound abciximab even lasts for up to 2 weeks). Thus, receptor blockade with abciximab can 
be reduced in patients with a strongly elevated PLT count. Due to the fact that internal GP 
IIb-IIIa receptors cannot adequately be blocked, TRAP-induced aggregation is only very 
incompletely be inhibited by standard doses of FRAs (in contrast to ADP induced 
aggregation that must completely be inhibited). Consequently, patients with ACS 
experience a markedly lower inhibition of aggregation than do patients with stable coronary 
artery disease. This suggests that higher doses of FRAs are required under conditions of 
increased PLT activation, especially with thrombin (occurring e.g. during fibrinolysis 
therapy). Additionally, the release of internal GP IIb-IIIa receptors can lead to a significant 
residual aggregation and thrombus formation despite the administration of FRAs.  
Novel antiplatelet strategies  
Currently, two groups of PLT inhibitors are approved for clinical use in ACS patients: ASA 
and oral TPs. These agents have shown improved short- and long-term clinical outcomes 
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but are associated with increased bleeding events. Thus, there is a need for new antiplatelet 
agents with higher PLT inhibition capacity and less bleeding risk.  
A new TxA2 receptor antagonist was tested in animals and has demonstrated fast and 
potent antiplatelet efficacy [47] comparable to that of ASA plus clopidogrel [48]. Additional 
desired effects were an improved endothelial function [49], an inhibited TxA2-induced 
vasoconstriction [50], and a favorable bleeding risk profile [48]. Picotamide, already marketed 
in Italy, combines both TxA2 receptor and thromboxane synthetase blockade and, unlike 
ASA, preserves prostacyclin formation in endothelial cells. Picotamide was shown to reduce 
atherosclerotic plaque progression, cardiovascular events and mortality without increased 
bleedings in ASA-refractory patients with peripheral artery disease without [51,52] or with 
diabetes [53]. Selective inhibition of the thrombin specific PAR-1 receptor (vorapaxar, 
atopaxar) represents a further strategy to reduce ischemic events and was tested in two 
Phase-II trials (TRA-PCI and LANCELOT-ACS) as secondary prophylaxis of ACS or on the 
top of standard antithrombotic therapy including ASA, clopidogrel and the heparin of 
choice. Despite significant dose-dependent increases in abnormal liver function parameters 
and QT elongation, there was a trend towards lower adverse cardiac events without 
increased bleeding events in the verum- vs. the placebo treated groups [54,55]. The first 
developed phosphodiesterase (PDE) inhibitor with an antiplatelet effect was dipyridamole. 
Together with ASA, dipyridamole demonstrated efficacy in the prevention of stroke [56]. 
However, ASA plus dipyridamole was not superior to clopidogrel in the prevention of 
recurrent stroke as seen in PRoFESS [57]. Cilostazol, a selective PDE III inhibitor, increases 
cAMP levels in PLTs, endothelial and smooth muscle cells leading to vasodilatatory and 
antiplatelet properties. Recent studies have shown that the addition of cilostazol to ASA and 
clopidogrel (triple antiplatelet therapy), particularly in diabetic patients, reduced risk of 
stent thrombosis (even of drug eluting stents) and increased cardiac outcomes after PCI 
without increased bleeding complications. However, due to headache, palpitations, and 
diarrhea, withdrawal of cilostazol approximated 15% [58,59]. Further antiplatelet strategies 
including blockade of inflammatory substances such as p selectin [60] or collagen receptors 
[61] are currently under clinical development. An accurate evaluation of the balance 
between the anti-ischemic effect and the hemorrhagic risk of these new drugs is highly 
warranted. 
Antiplatelet-therapy-inherited bleeding risk 
Sufficient hemostasis requires normal PLT function in at least 20% of circulating PLTs [62]. 
As the effects of antiplatelet drugs are not reversible by other drugs, PLT transfusions are 
the only manner to rapidly restore normal hemostasis. Today, prevention of cardiac events, 
especially stent thrombosis, is considered as being highly dependent on antiplatelet therapy 
during the first year after coronary intervention. In this period, however, up to 5% of 
patients have to undergo surgery for non cardiac reasons, whereby elderly patients, women, 
patients with anemia, renal dysfunction, and hypertension are at especially increased risk 
for perioperative bleeding. Not only does bleeding constitute an immediate threat, but is 
also associated with increased re-infarction and cardiac morbidity (5-fold/year) both in the 
short as well as the long term [63]. For this reason, the inherited bleeding risk of all 
antiplatelet drugs has to be outweighed against the concomitant cardioprotective effect 
(Tab.4.). Of note, antiplatelet replacement by heparin does not provide protection against 
the risk of coronary artery or stent thrombosis. Based on a retrospective evaluation, we 
recommended discontinuation of antiplatelet therapy for at least 2 days prior to elective  
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Pharmacological properties Indication (RRR) Bleeding risk 
GP IIb-IIIa antagonists
Fibrinogen receptor 
antagonists  
IST (50%) SP: 3 - 4% (mostly catheters) 
Clopidogrel (300 mg LD, 75/d mg MD)
ADP receptor antagonist 
AMI in ACS (18%) 
IST, recurrent ST (30%) 
SP: 1 – 2% (higher plus ASA) 
ICH: 0.35% 
GIT: 0.68% 
GIT ulcers: 0.68% 
IOBL: 50% (ASA + 
clopidogrel) * 
Acetylic salicylic acid ASA (100 – 325 mg/d)
COX-1 inhibitor 
Prim. prevention (40%) 
Sec. prevention (20%) 
SP: 1 ‰/year
ICH: 0.49% 
GIT: 2.66% 
GIT ulcers: 1.15% 
IOBL: 20%* 
PCI percutaneous coronary intervention; LD loading dose; MD maintenance dose; AMI acute 
myocardial infarction; ACS acute coronary syndrome; ST stent thrombosis; IST immediate stent 
thrombosis; SP spontaneous; ICH intracranial hemorrhage; GIT gastrointestinal; intraoperative blood 
loss; * without bleeding-related increase in mortality. 
The risk of cardiac events is maximal (increased up to 5-10-fold) in malignancy, diabetes mellitus, the 
early postoperative state and during stent re-endothelialization, especially of high risk stents (proximal, 
multiple, or overlapping stents, small vessels, bifurcated lesions). In these settings, the risk for stent 
thrombosis averages 35%. The associated mortality reaches 20-40% 
Table 4. Relative risk reduction (RRR) and bleeding risk of common antiplatelet substances 
[59] 
surgery [64]. However, since antiplatelet agents are maximally helpful when the thrombotic 
risk is highest, long-term dual antiplatelet therapy should be pursued until surgery, 
especially during stent re-endothelialization (4 – 6 weeks after bare metal stents, 12 months 
after drug-eluting stents). Due to the rise in fibrinogen, CRP and PAI-1, the risk of plaque 
rupture and consecutive thrombosis is maximal (2-4-fold higher) in the early postoperative 
setting. Here, the mortality rate due to stent thrombosis is estimated to about 20-40% [65]. 
After withdrawal of ASA, the cardiac complication rate increases 3-fold, and ASA should 
never be stopped when prescribed for secondary prophylaxis of ACS or in patients with 
stents. When prescribed for primary prevention, there is no evidence that ASA withdrawal 7 
days prior to surgery is harmful. Clopidogrel withdrawal during the first month after 
coronary intervention makes patients 10 times more likely to die. When necessary, ADP 
receptor blockers could be bridged with short acting GP IIb-IIIa antagonists like eptifibatide. 
After surgery, both drugs ASA and clopidogrel should be resumed within 12-24 hours. 
4. Antiplatelet therapy and coronary heart disease 
Primary and secondary prophylaxis of cardiac syndromes 
Since > 50 years ASA reduces vascular death by 15% and non-fatal vascular events by 30% 
as evidenced by meta-analyses of over 100 randomized trials [66,67]. ASA may also be of 
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benefit in the primary prevention of cardiovascular events but the effect is more modest and 
its recommendation in this setting is highly debated due to the probably offset of the 
cardioprotective effect by bleeding complications [68,69]. Additionally, total mortality 
remains unaffected. Based on these and further data [70-74] daily doses of 160-325 mg ASA 
are recommended for all subjects > 50 years of age, who are at increased risk of AMI. Higher 
doses are not more effective in the prevention of cardiovascular events and may be 
associated with more serious side effects (reduced patient compliance) [33]. Younger 
subjects should use ASA only, when manifestations of atherosclerotic diseases (e.g. TIA, 
unstable angina) are present [8].  
The CAPRIE study [75] examined the prophylactic efficacy of clopidogrel in comparison to 
ASA in patients with a history of ischemic stroke, prior AMI or symptomatic peripheral 
artery disease (PAD). In comparison to ASA (325 mg/d), a significant 8.7% risk reduction of 
non-fatal and fatal vascular deaths was found for clopidogrel (75 mg/d), which thereby 
occupies a firm place in secondary prophylaxis of cardiovascular events but is only 
marginally superior over ASA. Although not significant, ASA showed a trend towards 
better efficacy after prior AMI, whereas patients with PAD appeared to more profit from 
clopidogrel than from ASA. Despite this, a large portion of patients remains for whom no 
satisfactory therapeutic success can be obtained with ASA or clopidogrel monotherapy. 
Since both antiplatelet drugs have different target receptors and mechanisms of action 
(COX-1 inhibitor vs. P2Y12 ADP receptor blockade), their combination as dual antiplatelet 
therapy offers additive effects and provides greater inhibition of PLT aggregation than 
therapy with either agent alone. As a consequence, the CURE study [76] demonstrated a risk 
reduction of 20% in patients with unstable angina, when ASA was combined with 
clopidogrel. The subsequent CREDO trial [77] showed that dual antiplatelet therapy 
reduced the risk of major adverse cardiovascular events after angioplasty compared with 
ASA alone. The tolerability profile was good, and major bleedings increased by only 1% as 
demonstrated in CLARITY-TIMI 28 [78] and COMMIT [79]. In the CHARISMA trial, 
however, patients with established vascular disease demonstrated a markedly increased 
bleeding risk, and no additional benefits were achieved with dual antiplatelet therapy over 
ASA therapy alone (probably due to clopidogrel resistance) [42]. Long-term dual antiplatelet 
therapy was beneficial only for high-risk patients with clinically evident atherothrombosis, 
especially for the prevention of stroke in cases with atrial fibrillation [80].  
Fibrinolysis 
Thrombin liberation in the region of the lysed thrombus may promote increased activation 
of circulating PLTs [81]. Moreover, due to high amounts of PAI-1, the PLT-rich core (white) 
thrombus is practically resistant to fibrinolytic agents. For these reasons, a successful 
reperfusion upon fibrinolysis can be achieved in only 50% of AMI and a TIMI-3 flow, which 
is a decisive survival parameter, is only insufficiently restored. For these reasons, 
antiplatelet drugs have been administered together with fibrinolytics: full dose fibrinolytics 
plus partial dose FRAs [82] or reduced-dose fibrinolytics plus full dose FRAs [83]. Pooled 
results from these studies and equivalent data suggest that FRAs together with ASA 
significantly increase the efficacy of fibrinolytics, reduce fatal and non fatal re-infarctions 
and the need for urgent revascularization [84-86]. Drawbacks, however, were increased 
intracranial bleeding and unaffected re-infarction rates after 30 days asking for safety and 
long-term efficacy of this combination [87]. 
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Percutaneous transluminal coronary angioplasty (PTCA) 
Pretreatment with ASA as well as with TPs significantly lower (up to 70%) the incidence of 
early acute thrombotic occlusions after PTCA [8]. Since the additional administration of 
FRAs to ASA and/or clopidogrel as well as to standard therapy including anticoagulants, 
nitrates, and beta-blockers, further reduce (40%) early cardiac incidents (partly, however, at 
cost of increased bleeding events [88-105]), the ACC/AHA guidelines recommend the 
addition of a FRA to ASA and heparin to patients in whom catheterization and coronary 
intervention are planned [106]. Furthermore, eptifibatide or tirofiban together with ASA and 
heparin should be given to patients with continuing ischemia or elevated troponin levels, in 
whom invasive management is not planned. Clopidogrel administered before cardiac 
catheterization enhances perioperative bleeding, if angiography reveals that bypass grafting 
is required rather than percutaneous coronary intervention. Thus, the American College of 
Chest Physicians (ACCP) guidelines recommend withholding clopidogrel until the coronary 
anatomy is determined [107]. Despite the efficacy of antiplatelet therapy concerning early 
thrombotic occlusions after PTCA, studies on the prevention of later re-stenosis (> 6 month) 
were disappointing [108,109]. Due to an excessive fibroproliferative response, up to 30% of 
PTCA patients developed recurrent ischemia and re-stenosis [110]. Only the results of the 
TACTICS study [104] showed that in patients with ACS early invasive strategy combined 
with immediate administration of FRAs was significantly better concerning late vascular 
deaths than the “wait and see” approach. Patients with elevated troponin levels had the 
greatest benefit from this strategy [8]. 
Coronary stenting 
2 million patients of Western Countries undergo coronary dilatation each year [77], and 
coronary stents are placed in over 90% of these patients [111]. One of the greatest fears is 
subacute stent thrombosis triggered within minutes to hours after coronary intervention by 
activated PLTs. Predictors for increased risk of re-thrombosis are elevated GP IIb-IIIa 
expression or PLT degranulation markers prior to PCI as well as high post-interventional 
PLT reactivity to ADP [112]. Thus, long-term antiplatelet therapy is mandatory for the 
success of coronary stenting.  
One of the first trials on stent thrombosis showed that ticlopidine (vs. anticoagulants) 
reduced the risk [113]. Thereafter, numerous clinical trials have demonstrated the 
superiority of dual antiplatelet therapy [114-116]. Based on these data, the American Heart 
Association/American College of Cardiology guidelines recommend ASA plus a 300 mg or 
600 mg (better PLT inhibition) clopidogrel loading, followed by a 75 mg clopidogrel 
maintenance for 12 months for all patients undergoing PCI and/or stenting [117]. Recently, 
prasugrel demonstrated even higher efficiency than clopidogrel (plus 52%) irrespective of 
the clopidogrel loading dose: 300 mg [40] or 600 mg [39], however at cost of increased 
bleeding (2.4% vs. 1.8%, p=0.03) [40]. Moreover, the additional application of FRAs prior to 
PCI has significantly increased clinical outcomes as seen by improvements in early and late 
TIMI 3 flow rate, global left ventricular function, early re-stenosis, and recurrent ischemia 
[89,91,92,105,118,119] in spite of bleeding complications [92]. Abciximab could promote the 
re-establishment of the microcirculation, thus the functional recovery of the infarcted heart 
region. From the STOP-AMI trial [120] stenting + abciximab + dual antiplatelet therapy was 
superior over fibrinolysis with respect to myocardial salvage and the accumulation of death 
and thromboembolic complications for up to 6 months (p=0.02) and resulted in superior 
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inhibition of inflammation [28]. In the ERASER study [121], however, the rate of late re-
infarction (> 6 month) remained unaffected.  
5. Conclusion 
Despite its efficacy, ASA is a relatively weak antiplatelet drug, and ADP receptor 
antagonists like clopidogrel are only marginally superior to ASA in the reduction of AMI 
and stroke. Furthermore, adverse ischemic events probably due to drug resistance remain a 
serious clinical problem. The combination of different antiplatelet substances may implicate 
additive properties and is proven to be beneficial for patients, in whom monotherapy is not 
sufficient (non-responders) or who implicate a high thrombotic risk after coronary 
interventions. Given the predominate role of PLTs in the mechanism of stent thrombosis, 
dual antiplatelet therapy has reduced its incidence to less than 1.5% in most recent studies. 
Meanwhile, the combination of several (even three) antiplatelet drugs has become the 
standard of care in these situations. A future challenge, however, is to depict patients at 
especially high risk for post-interventional thrombotic complications, who may have 
additional benefit from the optimal antiplatelet therapy, probably with new antiplatelet 
regimens. 
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